Atlas Trials

Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Clinical trial NCT01325701 · COMPLETED

Trial details

NCT number
NCT01325701
Sponsor
Pharmacyclics LLC.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large Cell B-lymphoma
Start date
2011-05-01
Primary completion
2014-10-01
Enrollment
78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.